GREAT BRITAIN women’s football team have confirmed they will take the knee before the kick-off of their matches at the Tokyo Olympics.
With their first game scheduled next week against Chile, the squad have welcomed the recent clarification provided by the International Olympic Committee (IOC) on Rule 50 to allow athletes to make gestures on the field of play, provided they do so without disruption and with respect for fellow competitors.
Defender Demi Stokes said the Great Britain's women's football squad "feel strongly" about their decision to take the knee before games at the Tokyo Olympics this month.
"We know we have a big part to play. It's important we use our platforms to help in any way we can," said Stokes.
"We all feel strongly as individuals and as a team. We all understand what's been going on around racism and discrimination. It is the people that don't have a voice that we are standing up for.”
Team’s manager, Hege Riise, said that the players and staff have been taking the knee at club and international level for over a year now and “we were all united in our decision to continue doing whatever we can to raise awareness of racism and discrimination in all its forms”.
British Olympic Association's (BOA) Andy Anson added: "By taking the knee, our women's football side are embodying the values of Team GB."
Chelsea goalkeeper Carly Telford said it was "one of the first things we discussed as a group" and they were keen to make a statement as one of the first nations to compete at the Olympics.
Players take a knee ahead of the UEFA EURO 2020 final football match. (Photo by FACUNDO ARRIZABALAGA / POOL / AFP) via Getty Images)
Gesture of taking the knee was started by American footballer Colin Kaepernick who did it during the national anthem before a match in 2016 and it has since become a prominent symbol in sport and during anti-racism protests.
Following the murder of George Floyd last year, players and officials in the Premier League and EFL took the knee on the restart of the 2019-20 season in June 2020 to highlight racial inequality and discrimination.
Women's football followed suit during the 2020-21 season, alongside national teams.
Last month, England men's international Tyrone Mings said the team wanted to "educate and inform" in response to criticism from home secretary Priti Patel for taking the knee.
She had previously described taking the knee as "gesture politics".
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.